Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Proceedings Aacr Nci Eortc International Conference
Download Proceedings Aacr Nci Eortc International Conference full books in PDF, epub, and Kindle. Read online Proceedings Aacr Nci Eortc International Conference ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Head and Neck Cancer by : Bruce Brockstein
Download or read book Head and Neck Cancer written by Bruce Brockstein and published by Springer Science & Business Media. This book was released on 2006-04-18 with total page 380 pages. Available in PDF, EPUB and Kindle. Book excerpt: Exciting advances are occurring in the understanding of the molecular pathogenesis of squamous head and neck cancers. Epidemiology, staging and screening, as well as premalignancy, chemoprevention and the molecular biology of head and neck cancer, lay the groundwork for the understanding of the clinical chapters that follow. Controversial treatments will be compared to the standard management of patient care. Therapy chapters are divided into stage or category specific (resectable advanced, unresectable advanced or metastatic) problems, allowing the reader to review the current standards and options for patient types or specific patients easily. Considerations of supportive care, late toxicities and quality of life, often overlooked are reviewed in detail. This is a comprehensive summary of the current state of the art research and treatment.
Book Synopsis Antibody-Drug Conjugates and Immunotoxins by : Gail Lewis Phillips
Download or read book Antibody-Drug Conjugates and Immunotoxins written by Gail Lewis Phillips and published by Springer Science & Business Media. This book was released on 2012-12-13 with total page 370 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Book Synopsis Extracellular Targeting of Cell Signaling in Cancer by : James W. Janetka
Download or read book Extracellular Targeting of Cell Signaling in Cancer written by James W. Janetka and published by John Wiley & Sons. This book was released on 2018-07-23 with total page 482 pages. Available in PDF, EPUB and Kindle. Book excerpt: International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development. A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.
Book Synopsis Proteasome Inhibitors in Cancer Therapy by : Julian Adams
Download or read book Proteasome Inhibitors in Cancer Therapy written by Julian Adams and published by Springer Science & Business Media. This book was released on 2004-05-25 with total page 319 pages. Available in PDF, EPUB and Kindle. Book excerpt: A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Author :William J. LaRochelle Publisher :Springer Science & Business Media ISBN 13 :1592598935 Total Pages :745 pages Book Rating :4.5/5 (925 download)
Book Synopsis The Oncogenomics Handbook by : William J. LaRochelle
Download or read book The Oncogenomics Handbook written by William J. LaRochelle and published by Springer Science & Business Media. This book was released on 2007-11-09 with total page 745 pages. Available in PDF, EPUB and Kindle. Book excerpt: An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Book Synopsis Animal Models for the Development of Cancer Immunotherapy by : Seng-Lai Tan
Download or read book Animal Models for the Development of Cancer Immunotherapy written by Seng-Lai Tan and published by John Wiley & Sons. This book was released on 2022-08-23 with total page 324 pages. Available in PDF, EPUB and Kindle. Book excerpt: Animal Models for the Development of Cancer Immunotherapy Provides readers with a clear understanding of the value and challenges of using common and emerging preclinical models in cancer immunotherapy research and development. Animal models are essential tools for studying a range of issues in preclinical and clinical research on therapies targeting cancerous tumors. As clinical trials of advances in cancer immunotherapy are predicted to outpace preclinical research in the near future, there remains an urgent need to develop better animal models for preclinical evaluation of novel modulators. Animal Models for the Development of Cancer Immunotherapy provides a detailed overview of different preclinical model systems for development of novel cancer immunotherapies while highlighting how key aspects of individual models translate into clinical findings. Covering the introduction, development, and therapeutic applications of animal models for cancer immunotherapy, this comprehensive volume helps pharmacologists identify suitable animal models, design pharmacological or translational studies, and advance their mechanistic understanding of therapeutic agents, and increase the possibility of success for novel immunotherapies in clinical settings. Chapters written by prominent leaders in the field address specific models that evaluate immuno-oncology drugs are supported by in-depth case studies and extensive references throughout. Emphasizes the importance of modeling tumor metastasis in preclinical models for efficient translation of findings into the clinic Explores recently discovered mechanisms of resistance and their preclinical modeling Highlights the unique characteristics and features of autologous and allogeneic approaches for humanization of mouse models Reviews development of bone marrow-liver-thymus (BLT) immune humanized mice and emerging alternative models such as genetically engineered mouse models (GEMM) Discusses alternative animal models for cancer research such as severe combined immunodeficiency (SCID) pigs Animal Models for the Development of Cancer Immunotherapy is an essential resource for scientists and researchers in the pharmaceutical and biotechnology industries, medicinal chemists and biochemists, cell and molecular biologists, pharmacologists, immunologists, and clinicians.
Book Synopsis Patient-Derived Mouse Models of Cancer by : Robert M. Hoffman
Download or read book Patient-Derived Mouse Models of Cancer written by Robert M. Hoffman and published by Springer. This book was released on 2017-08-01 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt: This text highlights seminal discoveries and also provides comprehensive and state-of the-art approach to mouse models of human patient tumors. These areas include training, basic techniques, as well as general troubleshooting. Subsequent chapters focus on the different mouse models of patient tumors including the various strains of immunodeficient mice currently available and the transplantation techniques that can be used as well as state-of-the-art imaging techniques. Practical applications of the models from drug discovery, genome analysis to personalized treatment are also covered. Written by experts in that field, each of these sections address these critical issues. A brief review of the existing literature addressing the particular topic follows in each section. Presently, there is no single source to provide information on technique and uses of mouse models of human patient tumors. Patient-Derived Mouse Models of Cancer will satisfy this need for cancer researchers, oncologists, pharmaceutical and biotechnology industry scientists as well as molecular biologists studying in vivo systems
Download or read book Cancer II written by Michael J. Waring and published by Springer. This book was released on 2019-01-25 with total page 482 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.
Book Synopsis PARP Inhibitors for Cancer Therapy by : Nicola J. Curtin
Download or read book PARP Inhibitors for Cancer Therapy written by Nicola J. Curtin and published by Humana Press. This book was released on 2015-06-13 with total page 590 pages. Available in PDF, EPUB and Kindle. Book excerpt: PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of discovery of the PARP family, and other DNA maintenance-associated PARPs will also be discussed. The volume also features a section on accessible chemistry behind the development of inhibitors. PARP inhibitors are a group of pharmacological inhibitors that are a particularly good target for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA damaging agents used to treat cancer. Researchers have learned a tremendous amount about the biology of PARP and how tumour-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy and has led to a heightened activity in this area.
Book Synopsis Drugs for HER-2-positive Breast Cancer by : Maria Sibilia
Download or read book Drugs for HER-2-positive Breast Cancer written by Maria Sibilia and published by Springer Science & Business Media. This book was released on 2011-01-06 with total page 118 pages. Available in PDF, EPUB and Kindle. Book excerpt: Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Download or read book Advances in Cancer Research written by and published by Elsevier. This book was released on 2011-07-29 with total page 429 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.
Book Synopsis From Molecular to Modular Tumor Therapy: by : Albrecht Reichle
Download or read book From Molecular to Modular Tumor Therapy: written by Albrecht Reichle and published by Springer Science & Business Media. This book was released on 2010-09-09 with total page 552 pages. Available in PDF, EPUB and Kindle. Book excerpt: Presenting a holistic and abstract perspective of tumors, this volume aims to provide personalized diagnostic and therapeutic strategies for the control of metastatic tumor disease. Readers will find ways to record tumor biology that are based on different sciences, in addition to other strategies.
Book Synopsis Nucleic Acid Nanotheranostics by : Marco Filice
Download or read book Nucleic Acid Nanotheranostics written by Marco Filice and published by Elsevier. This book was released on 2019-02-26 with total page 494 pages. Available in PDF, EPUB and Kindle. Book excerpt: Nucleic Acid Nanotheranostics: Biomedical Applications offers a comprehensive overview of improvements and new trends in fabrication of nanostructures as theranostic multifunctional carriers in gene therapy. With a strong focus on medical applications (comprising diagnosis, therapy and imaging), the book also examines gene therapy in an individual patient's cells or tissues to treat genetic diseases. Sections cover Biomedical and Diagnostic applications of Nucleic Acids, Biologic and Synthetic Advanced Nanostructures for nucleic acid delivery, and important considerations of nanomedicine. This book is a valuable guide for materials scientists, physicians, chemists and engineers, but is also ideal for clinicians wishing to expand their knowledge. - Provides a unique source of knowledge (theoretical as well as practical) on nanotheranostic materials for gene therapy at all levels and related scientific areas - Covers the pros and cons related to viral and nanomaterial-based delivery of nucleic acids in terms of biosafety, carrier selection, synthesis and bioimaging - Presents the only book to include an analysis of nanoformulations approved for clinical use
Book Synopsis Single-Arm Phase II Survival Trial Design by : Jianrong Wu
Download or read book Single-Arm Phase II Survival Trial Design written by Jianrong Wu and published by CRC Press. This book was released on 2021-07-19 with total page 273 pages. Available in PDF, EPUB and Kindle. Book excerpt: Single-Arm Phase II Survival Trial Design provides a comprehensive summary to the most commonly- used methods for single-arm phase II trial design with time-to-event endpoints. Single-arm phase II trials are a key component for successfully developing advanced cancer drugs and treatments, particular for target therapy and immunotherapy in which time-to-event endpoints are often the primary endpoints. Most test statistics for single-arm phase II trial design with time-to-event endpoints are not available in commercial software. Key Features: Covers the most frequently used methods for single-arm phase II trial design with time-to-event endpoints in a comprehensive fashion. Provides new material on phase II immunotherapy trial design and phase II trial design with TTP ratio endpoint. Illustrates trial designs by real clinical trial examples Includes R code for all methods proposed in the book, enabling straightforward sample size calculation.
Book Synopsis Cancer Chemotherapy and Biotherapy by : Bruce A. Chabner
Download or read book Cancer Chemotherapy and Biotherapy written by Bruce A. Chabner and published by Lippincott Williams & Wilkins. This book was released on 2010-11-08 with total page 836 pages. Available in PDF, EPUB and Kindle. Book excerpt: Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.
Book Synopsis Targeted Cancer Therapy by : Razelle Kurzrock
Download or read book Targeted Cancer Therapy written by Razelle Kurzrock and published by Springer Science & Business Media. This book was released on 2008-03-07 with total page 447 pages. Available in PDF, EPUB and Kindle. Book excerpt: Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.
Book Synopsis Targeting the DNA Damage Response for Anti-Cancer Therapy by : John Pollard
Download or read book Targeting the DNA Damage Response for Anti-Cancer Therapy written by John Pollard and published by Springer. This book was released on 2018-05-26 with total page 402 pages. Available in PDF, EPUB and Kindle. Book excerpt: Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.
